跳至主要内容
临床试验/NCT03699345
NCT03699345已完成不适用

Post-Market Clinical Follow-up Study to Monitor Device Performance and Outcomes of the CENTERA Transcatheter Heart Valve System

Edwards Lifesciences11 个研究点 分布在 6 个国家目标入组 87 人开始时间: 2019年1月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
87
试验地点
11
主要终点
All-Cause Mortality

研究概览

简要总结

This study will monitor device performance and safety of the Edwards CENTERA Transcatheter Heart Valve (THV) system in patients with severe, symptomatic aortic valve stenosis who are indicated for aortic valve replacement.

详细描述

A prospective, international, single arm, multi-center post market clinical follow-up study.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Severe native valve calcific aortic stenosis
  • Judged by the Heart Team to be at high or greater risk for open surgical therapy (i.e. predicted risk of surgical mortality greater than or equal to 8% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the risk calculator).

排除标准

  • Known hypersensitivity to Nitinol (nickel or titanium)
  • Evidence of intracardiac mass, thrombus, vegetation, active infection or endocarditis
  • Inability to tolerate anticoagulation/antiplatelet therapy

结局指标

主要结局

All-Cause Mortality

时间窗: 30 days

All-cause mortality at 30 days

次要结局

未报告次要终点

研究者

发起方
Edwards Lifesciences
申办方类型
Industry
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验